Inhibikase Therapeutics (IKT) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
X4 Pharmaceuticals is the larger company by market cap ($278.6 million vs $270.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | IKT | XFOR |
|---|---|---|
| Share price | $1.94 | $2.81 |
| Market cap | $270.70M | $278.60M |
| 1-day change | -2.02% | +1.44% |
| P/E ratio (TTM) | — | 140.50 |
| EPS (TTM) | $-0.43 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $4.83 |
| 52-week low | $1.33 | $2.70 |
| Distance from 52-week high | -25.67% | -41.82% |
| Average volume | 665.95K | 843.96K |
| Shares outstanding | 139.54M | 99.15M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
IKT vs XFOR FAQ
Which is bigger, Inhibikase Therapeutics or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $278.60M compared with $270.70M for Inhibikase Therapeutics (IKT).
Are Inhibikase Therapeutics and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.